An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i

Superseded

This Document Has Been Replaced By:

i

Retired

This Document Has Been Retired

i

Up-to-date Information

This is the latest update:

An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge
Filetype[PDF-2.23 MB]


Details:
No Related Documents.

You May Also Like:

  1. Filetype[PDF - 1.87 MB]
    Personal Author:
    Gao, Jin; Couzens, Laura; Burke, David F.; Wan, Hongquan; Wilson, Patrick; Memoli, Matthew J.; Xu, Xiyan; Harvey, Ruth; Wrammert, Jens; Ahmed, Rafi; Taubenberger, Jeffery K.; Smith, Derek J.; Fouchier, Ron A. M.; Eichelberger, Maryna C.;
    Published Date:
    April 09 2019
    Source:
    mBio. 10(2)
    Description:
    The effectiveness of influenza vaccines against circulating A(H1N1)pdm09 viruses was modest for several seasons despite the absence of antigenic drift of hemagglutinin (HA), the primary vaccine component. Since antibodies against HA and neuraminidase...
    File Type:
    Filetype[PDF - 1.87 MB]
  2. Filetype[PDF - 1.04 MB]
    Personal Author:
    Marjuki, Henju; Mishin, Vasiliy P.; Chesnokov, Anton P.; Jones, Joyce; De La Cruz, Juan A.; Sleeman, Katrina; Tamura, Daisuke; Nguyen, Ha T.; Wu, Ho-Sheng; Chang, Feng-Yee; Liu, Ming-Tsan; Fry, Alicia M.; Cox, Nancy J.; Villanueva, Julie M.; Davis, Charles T.; Gubareva, Larisa V.;
    Published Date:
    August 14 2014
    Source:
    J Infect Dis. 211(2):249-257
    Description:
    Background.Patients contracting influenza A(H7N9) infection often developed severe disease causing respiratory failure. Neuraminidase (NA) inhibitors (NAIs) are the primary option for treatment, but information on drugresistance markers for influenza...
    File Type:
    Filetype[PDF - 1.04 MB]
  3. Filetype[PDF - 3.28 MB]
    Personal Author:
    Marjuki, Henju; Mishin, Vasiliy P.; Chai, Ning; Tan, Man-Wah; Newton, Elizabeth M.; Tegeris, John; Erlandson, Karl; Willis, Melissa; Jones, Joyce; Davis, Todd; Stevens, James; Gubareva, Larisa V.;
    Published Date:
    November 14 2016
    Source:
    J Virol. 2016; 90(23):10446-10458
    Description:
    The pandemic threat posed by emerging zoonotic influenza A viruses necessitates development of antiviral agents effective against various antigenic subtypes. Human monoclonal antibody (hMAb) targeting the hemagglutinin (HA) stalk offers a promising a...
    File Type:
    Filetype[PDF - 3.28 MB]
  4. Filetype[PDF - 2.31 MB]
    Personal Author:
    Li, Pi-Chun; Liao, Mei-Ying; Cheng, Ping-Chang; Liang, Jian-Jong; Liu, I-Ju; Chiu, Chien-Yu; Lin, Yi-Ling; Chang, Gwong-Jen J.; Wu, Han-Chung;
    Published Date:
    May 01 2012
    Source:
    PLoS Negl Trop Dis. 2012; 6(5).
    Description:
    BackgroundDengue virus (DENV) is a significant public health threat in tropical and subtropical regions of the world. A therapeutic antibody against the viral envelope (E) protein represents a promising immunotherapy for disease control.Methodology/P...
    File Type:
    Filetype[PDF - 2.31 MB]
  5. Filetype[PDF - 1.06 MB]
    Personal Author:
    Wilson, Jason R.; Guo, Zhu; Reber, Adrian; Kamal, Ram P.; Music, Nedzad; Gansebom, Shane; Bai, Yaohui; Levine, Min; Carney, Paul; Tzeng, Wen-Pin; Stevens, James; York, Ian A.;
    Published Date:
    Oct 03 2016
    Source:
    Antiviral Res. 135:48-55.
    Description:
    Zoonotic A(H7N9) avian influenza viruses emerged in China in 2013 and continue to be a threat to human public health, having infected over 800 individuals with a mortality rate approaching 40%. Treatment options for people infected with A(H7N9) inclu...
    File Type:
    Filetype[PDF - 1.06 MB]